Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRUGNASDAQ:IMMXNYSE:PLXNASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$32.62+0.4%$32.99$0.93▼$79.02$229.78M-5.32824,122 shs31,741 shsIMMXImmix Biopharma$2.09$1.75$1.26▼$2.71$58.17M0.27122,801 shs53,064 shsPLXProtalix BioTherapeutics$1.46-15.1%$2.52$0.82▼$3.10$116.10M-0.05514,217 shs5.67 million shsPROKProKidney$0.75+4.0%$0.84$0.46▼$4.44$219.52M1.5691,348 shs622,271 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences0.00%-0.40%+11.13%-30.78%+2,922.36%IMMXImmix Biopharma0.00%-0.48%+33.55%+6.09%-4.13%PLXProtalix BioTherapeutics0.00%-42.67%-28.63%-32.55%+56.36%PROKProKidney0.00%-8.59%-1.35%-54.63%-74.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRUGBright Minds Biosciences3.3013 of 5 stars3.65.00.00.03.52.50.0IMMXImmix Biopharma3.2296 of 5 stars3.55.00.00.03.31.70.6PLXProtalix BioTherapeutics2.398 of 5 stars3.50.00.00.02.40.01.9PROKProKidney2.1722 of 5 stars3.30.00.00.02.64.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRUGBright Minds Biosciences 3.17Buy$83.25155.21% UpsideIMMXImmix Biopharma 3.00Buy$7.00234.93% UpsidePLXProtalix BioTherapeutics 3.00Buy$15.00927.40% UpsidePROKProKidney 2.50Moderate Buy$5.00566.67% UpsideCurrent Analyst Ratings BreakdownLatest IMMX, PLX, PROK, and DRUG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.002/19/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.00 ➝ $85.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRUGBright Minds BiosciencesN/AN/AN/AN/A$5.86 per shareN/AIMMXImmix BiopharmaN/AN/AN/AN/A$0.81 per shareN/APLXProtalix BioTherapeutics$53.40M2.17$0.08 per share17.80$0.47 per share3.11PROKProKidney$76K2,888.47N/AN/A($4.84) per share-0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRUGBright Minds Biosciences-$2.06M-$0.17N/AN/AN/AN/A-5.85%-5.68%5/21/2025 (Estimated)IMMXImmix Biopharma-$15.43M-$0.77N/AN/AN/AN/A-102.68%-80.89%N/APLXProtalix BioTherapeutics$8.31M$0.04N/A4.71N/A-21.03%-30.89%-11.74%N/APROKProKidney-$35.47M-$0.63N/AN/AN/AN/AN/A-10.24%N/ALatest IMMX, PLX, PROK, and DRUG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025N/ADRUGBright Minds Biosciences-$0.38N/AN/AN/AN/AN/A5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/A5/9/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/AN/A3/24/2025Q4 2024IMMXImmix Biopharma-$0.25-$0.16+$0.09-$0.16N/AN/A3/17/2025Q4 2024PROKProKidney-$0.14-$0.17-$0.03-$0.17N/A$0.08 million2/13/2025Q1 2025DRUGBright Minds Biosciences-$0.23$0.01+$0.24$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRUGBright Minds BiosciencesN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRUGBright Minds BiosciencesN/A126.0111.31IMMXImmix BiopharmaN/A3.473.47PLXProtalix BioTherapeuticsN/A1.981.27PROKProKidneyN/A17.0817.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRUGBright Minds Biosciences40.52%IMMXImmix Biopharma11.26%PLXProtalix BioTherapeutics16.53%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipDRUGBright Minds Biosciences42.66%IMMXImmix Biopharma48.90%PLXProtalix BioTherapeutics6.30%PROKProKidney41.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableIMMXImmix Biopharma927.83 million14.06 millionOptionablePLXProtalix BioTherapeutics20079.52 million69.00 millionOptionablePROKProKidney3292.70 million170.65 millionOptionableIMMX, PLX, PROK, and DRUG HeadlinesRecent News About These CompaniesProKidney Reports First Quarter 2025 Financial Results and Business HighlightsMay 12 at 4:15 PM | globenewswire.comAnother Big Office Landlord Tests Sales ClimateMay 12 at 3:45 PM | bankerandtradesman.comPROKIDNEY Earnings Preview: Recent $PROK Insider Trading, Hedge Fund Activity, and MoreMay 9 at 3:54 PM | nasdaq.comProKidney (PROK) Expected to Announce Earnings on FridayMay 8, 2025 | americanbankingnews.comProKidney (PROK) Expected to Announce Quarterly Earnings on FridayMay 4, 2025 | marketbeat.comWhy ProKidney Corp.’s (PROK) Stock Is Down 6.09%April 28, 2025 | aaii.comInsider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Purchases 387,393 Shares of StockApril 25, 2025 | insidertrades.comProKidney Corp. (NASDAQ:PROK) Insider Control Empresarial De Capital Acquires 100,000 SharesApril 20, 2025 | marketbeat.comInsider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Acquires 268,105 Shares of StockApril 18, 2025 | marketbeat.comWhy ProKidney Corp.’s (PROK) Stock Is Down 7.90%April 17, 2025 | aaii.comProKidney Corp. (NASDAQ:PROK) Insider Buys $195,716.65 in StockApril 17, 2025 | insidertrades.comInsider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Purchases 1,032,218 Shares of StockApril 16, 2025 | marketbeat.comGreensboro’s Once Great Win Is Now A ProKidney FailureApril 16, 2025 | rhinotimes.comControl Empresarial De Capital Buys 1,032,218 Shares of ProKidney Corp. (NASDAQ:PROK) StockApril 15, 2025 | insidertrades.comWhy ProKidney Corp.’s (PROK) Stock Is Down 9.90%April 10, 2025 | aaii.comWhy ProKidney Corp.’s (PROK) Stock Is Down 14.87%April 8, 2025 | aaii.comProKidney Corp.March 30, 2025 | wsj.comHere's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn SituationMarch 27, 2025 | finance.yahoo.comDown -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)March 21, 2025 | zacks.comProKidney reports larger loss in 2024 as production resumesMarch 18, 2025 | journalnow.comProKidney reports FY24 EPS (62c), consensus (59c)March 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMMX, PLX, PROK, and DRUG Company DescriptionsBright Minds Biosciences NASDAQ:DRUG$32.62 +0.13 (+0.40%) Closing price 04:00 PM EasternExtended Trading$32.62 0.00 (0.00%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Immix Biopharma NASDAQ:IMMX$2.09 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.06 -0.03 (-1.63%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Protalix BioTherapeutics NYSE:PLX$1.46 -0.26 (-15.12%) Closing price 04:00 PM EasternExtended Trading$1.48 +0.02 (+1.10%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.ProKidney NASDAQ:PROK$0.75 +0.03 (+3.96%) Closing price 04:00 PM EasternExtended Trading$0.80 +0.05 (+6.13%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
